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Methods
DH5α E. coli cell stock stored at -80°C, containing a pGEX vector with the 
wild  type  Lck  gene  was  subcultured in  4  mL of  LB liquid  medium and 
allowed to grow overnight while shaking at 250 rpm in 37°C. From these 
cells, the plasmid containing Lck was isolated using QIAprep Spin Miniprep 
Kit  (Qiagen).  Subsequent DNA sequencing confirmed the presence of  the 
wild type Lck gene correctly cloned in the reading frame of the N-terminal 
GST affinity tag. 
To purify wild type Lck enzyme, the plasmid was transformed into DH5α 
cells  and streaked on LB agar  ampicillin  plates  and incubated overnight. 
Transformed colonies  were  subcultured  in  500  mL of  LB  liquid  medium 
containing 50 "g/mL of  ampicillin and allowed to grow overnight  while 
shaking at 250 rpm in 37°C. After 12 hours, the culture was brought to room 
temperature and IPTG 50 "g/mL was added to induce Lck expression for 6 
hours. The cells were spun down at 5000 g for 30 minutes and the pellet 
saved at -20°C. Cell pellets were thawed and resuspended on ice in PBS lysis 
buffer.  To  lyse  the  cells,  the  cell  mixture  was  passed  through  a  French 
Pressure cell press 3 times. The lysate was then subjected to centrifugation at 
20,000 rpm at 4°C for 30 minutes. Supernatant was then incubated with 0.06 
g of  glutathione-agarose beads (Sigma) while shaking at  4°C for 2 hours. 
This  lysate  supernatant  was  passed  through  an  empty  chromatography 
column, washed 3 times with protocols specific for the GST-affinity tag, and 
finally  Lck  was  eluted  from  the  column.  Enzyme  concentration  was 
quantified using the Bradford assay according to a standard BSA curve.
We  used  the  QuikChange  protocol  to 
generate the Lck mutants from the wild 
type Lck plasmid and also engineered a 
substrate  specific  for  Lck.  Each 
QuikChange reaction was transformed 
into fresh competent DH5α E. coli cells. 
The  plasmids  for  the  mutants  were 
isolated  and  DNA  sequence  was 
confirmed.  The  same  purification 
protocol was used for each mutant and 
substrate as described above. 
A kinase assay was performed with Lck to test for wild type activity, while a 
western  blot  was  used  to  test  enzymatic  phosphorylation  of  the  Lck 
substrate by the wildtype and mutant enzyme. 
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Figure 5. Western blot of wild type Lck (lanes 1-3) and Pinsert 
Lck (lanes 4-6) enzymatic activity. Enzyme concentrations: lanes 
one and two 0.02 mg/mL, lanes two and five 0.05 mg/mL , and 
lanes three and six 0.2 mg/mL. The same concentration of Lck 
substrate was used for each lane. 
To determine if the activated Lck is responsible for the proliferation of CTV-1 
cells, we determined the sensitivity of CTV-1 cells to various kinase inhibitors 
that have different levels of inhibition for Lck. The results are shown in figure 6.. 
Bosutinib, Dasatinib and A770041 are Src family inhibitors with A770041 being 
the most selective inhibitor for Lck.  Sorafenib targets FLT3, an unrelated kinase, 
and was used as a control.  A770041 displayed an IC50 (concentration killing 
50% of the cells ) of.8 nM. Bosutinib, dasatinib, displayed IC50 values of 18 and 
3.6 nM.  In contrast sorafenib has an IC50 of 7000 nM toward CTV-1.  These 
results demonstrate that Lck is activated in CTV-1 cells and the activated Lck is 
responsible for CTV-1 proliferation. 
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Figure 2. Illustration of pGEX plasmid.
Lck contains a linker region located between its SH2 and kinase domains. 
Previous studies have shown that the linker plays an important inhibitory 
role in regulating Lck activation through its interaction with the SH3 and 
kinase domains. With this regulatory mechanism, we hypothesized that the 
Pinsert mutation in the linker region would disrupt Lck’s ability to adopt the 
inhibitory  conformation  resulting  in  increased  enzymatic  activity.  Our 
preliminary  results  in  figure  5demonstrate  that  the  Pinsert  Lck  mutation 
does indeed activate Lck.
Data in figure 6 show that A770041 was most effective in blocking CTV-1 cell 
proliferation.  Although  Bosutinib,  Dasatinib  and  A770041  all  target  Src 
family  kinases,  A770041  shows  the  strongest  inhibition.  Considering  that 
CTV-1  cells  contain  mutations  only  in  Lck,  and  not  in  other  Src  family 
kinases  like  Src  and Fyn,  we believe A770041 is  suppressing mutant  Lck 
activity. Together these data suggest that the Pinsert mutation in Lck found 
in CTV-1 cells causes the enzyme’s constitutive activation, uncontrolled cell 
proliferation, and therefore leukemia progression. 
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Figure 7. Ribbon structure of wild type Lck with domains labeled. 
The red region connecting the SH2 domain to the kinase domain 
is linker region.
Introduction
In the leukemia cancer cell line CTV-1, researchers 
have identified four characteristic mutations in the 
Lck gene.  As a member of  the Src  family kinases, 
Lck plays an integral role in regulating growth and 
division  in  immune  system  cells.  Leukemia 
develops  when  a  mutational  event  alters  a  white 
blood  cell’s  differentiation  pattern  and  causes  the 
cell to divide without control. As white blood cells 
xxbegin accumulating in the blood, they affect healthy cell function. With Lck’s 
role  in  signaling  for  cell  division,  we  hypothesized  that  the  identified 
mutations  result  in  Lck’s  constitutive  activation  causing  leukemia 
progression.  In  order  to  determine  how  these  mutations  affect  Lck 
activation, we used molecular techniques to introduce each mutation into a 
normally functioning Lck enzyme, engineered a substrate specific for Lck, 
and demonstrated that  one of  the mutations activates  Lck function.  This 
research  lays  a  foundation  for  understanding  the  oncogenic  basis  of  the 
CTV-1 cancer cell. 
Figure 1. Lck
Figure  6.  Inhibition  of  CTV-1  cells  by  targeted  drug  therapies.  Beginning  at  a 
concentration of 0.0006 uM, each drug was added at concentrations increasing by a 
factor of 10 until the max concentration of 20 uM. Cells were incubated with each drug 
for 72 hours before data collection. Data is courtesy of Dr. Li Li M.D. Ph.D. and Dr. 
Gongquin Sun Ph.D. 
Figure 5 shows the relative ability of each enzyme to phosphorylate the Lck 
substrate and also undergo autophosphorylation. The phosphorylation on Lck 
and the Lck mutant was determined by Western Blot using an antibody against 
phosphotyrosine. Lane 3 and lane 6 show the phosphorylation of wt Lck and 
the Lck insertion mutant and their ability to phosphorylate the Lck substrate. At 
an  enzyme  concentration  of  0.2  mg/,  the  Lck  band  staining  levels  are 
comparable  between the two lanes,  indicating that  the two enzymes have a 
similar  ability  to  autophosphorylate.  The  significantly  darker  band  at  the 
substrate level in lane six demonstrates that the Pinsert Lck mutant was more 
active  in  phosphorylating the  substrate  than the  wild  type Lck at  the  same 
enzyme concentration. This result indicates that the Pinsert Lck mutant is more 
active than the wild type enzyme.
